These properties make progenitor-exhausted CD8+ T cells a major determinant of responses to PD-1 axis blockade.533–536 Based on this synergistic effect of LSD1 inhibitors and PD-1 axis inhibitors, there is already an ongoing clinical trial evaluating this combination therapy in SCLC and LSCC patients (NCT04350463). The gene discussed is PDCD1; the disease is small cell lung carcinoma.